Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) EBT (2024 - 2025)

Pelthos Therapeutics has reported EBT over the past 2 years, most recently at -$28.6 million for Q4 2025.

  • Quarterly results put EBT at -$28.6 million for Q4 2025, down 1384.22% from a year ago — trailing twelve months through Dec 2025 was -$50.7 million (down 537.41% YoY), and the annual figure for FY2025 was -$50.7 million, down 537.41%.
  • EBT for Q4 2025 was -$28.6 million at Pelthos Therapeutics, down from -$16.7 million in the prior quarter.
  • Over the last five years, EBT for PTHS hit a ceiling of -$1.7 million in Q3 2024 and a floor of -$28.6 million in Q4 2025.